ZIM
VTGN icon

Zacks Investment Management’s VistaGen Therapeutics VTGN Stock Holding History

Zacks Investment Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-400
Closed -$23K – 672
2021
Q4 		$23K Hold
400
– – ﹤0.01% 598
2021
Q3 		$33K Buy
+400
New +$34.8K ﹤0.01% 592

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Zacks Investment Management's VTGN Position: Q1 2022 in Review

Zacks Investment Management sold out of VistaGen Therapeutics (VTGN) in Q1 2022, closing a stake of 400 shares — an estimated $23K sold.

Zacks Investment Management first reported a position in VTGN in Q3 2021 and held it in 2 quarters. The position peaked at $33K in Q3 2021. 116 funds tracked by Wall St. Rank hold VTGN as of Q1 2022.

  • Zacks Investment Management reported no remaining VistaGen Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Zacks Investment Management sold 400 VistaGen Therapeutics shares in Q1 2022, an estimated $23K.
  • Zacks Investment Management first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 2 quarters.
  • Zacks Investment Management's VistaGen Therapeutics position peaked at $33K in Q3 2021.
  • 116 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2022.

Based on Zacks Investment Management's 13F filing for Q1 2022, filed 13 May 2022.